Psychomotor performance of patients with rheumatoid arthritis: cross-over comparison of dextropropoxyphene, dextropropoxyphene plus amitriptyline, indomethacin, and placebo. 1988

U Saarialho-Kere, and H Julkunen, and M J Mattila, and T Seppälä
Department of Pharmacology and Toxicology, University of Helsinki, Finland.

Actions on performance of dextropropoxyphene (DXP) alone and in combination with amitriptyline (AMI), indomethacin (IN), and placebo were compared in 15 patients with rheumatoid arthritis. The patients were on their prescribed maintenance regimen excluding analgesics. In four randomized test sessions at two-week intervals, they received double blind and crossover single oral doses of DXP 130 mg, IN 50 mg, DXP 65 mg + AMI 25 mg or placebo, each after two days' pretreatment with the same drug. Objective and subjective effects were measured at baseline and 2 and 4 hours after drug administration. DXP impaired critical flicker discrimination, symbol copying and body balance without modifying tracking, choice reactions or attention. It rendered the subjects elated, muzzy, mentally slow and calm. Actions of AMI + DXP were about the same. IN impaired body balance and critical flicker recognition. Plasma concentrations of DXP were moderate to high whilst those of IN and AMI were fairly low. We conclude that therapeutic doses of DXP and IN are relatively safe in regard to driving skills. Small doses of AMI may not enhance the mild psychomotor effects of DXP. Earlier single dose studies carried out with healthy volunteers might have overestimated the decremental effects of analgesics on psychomotor performance.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011431 Dextropropoxyphene A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect. D-Propoxyphene,Darvon,Propoxyphene,Propoxyphene Hydrochloride,Propoxyphene Hydrochloride, (R*,R*)-(+-)-Isomer,Propoxyphene Hydrochloride, (R-(R*,R*))-Isomer,Propoxyphene Hydrochloride, (R-(R*,S*))-Isomer,Propoxyphene Hydrochloride, (S-(R*,R*))-Isomer,Propoxyphene Maleate, (+)-Isomer,Propoxyphene Phosphate, (S-(R*,S*))-Isomer,Propoxyphene Sulfate, (S-(R*,S*))-Isomer,D Propoxyphene,Hydrochloride, Propoxyphene
D011597 Psychomotor Performance The coordination of a sensory or ideational (cognitive) process and a motor activity. Perceptual Motor Performance,Sensory Motor Performance,Visual Motor Coordination,Coordination, Visual Motor,Coordinations, Visual Motor,Motor Coordination, Visual,Motor Coordinations, Visual,Motor Performance, Perceptual,Motor Performance, Sensory,Motor Performances, Perceptual,Motor Performances, Sensory,Perceptual Motor Performances,Performance, Perceptual Motor,Performance, Psychomotor,Performance, Sensory Motor,Performances, Perceptual Motor,Performances, Psychomotor,Performances, Sensory Motor,Psychomotor Performances,Sensory Motor Performances,Visual Motor Coordinations
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

U Saarialho-Kere, and H Julkunen, and M J Mattila, and T Seppälä
February 1974, Rheumatology and rehabilitation,
U Saarialho-Kere, and H Julkunen, and M J Mattila, and T Seppälä
January 1981, European journal of rheumatology and inflammation,
U Saarialho-Kere, and H Julkunen, and M J Mattila, and T Seppälä
January 1973, Scandinavian journal of rheumatology. Supplement,
U Saarialho-Kere, and H Julkunen, and M J Mattila, and T Seppälä
January 1976, Rheumatology and rehabilitation,
U Saarialho-Kere, and H Julkunen, and M J Mattila, and T Seppälä
January 1976, Scandinavian journal of rheumatology. Supplement,
U Saarialho-Kere, and H Julkunen, and M J Mattila, and T Seppälä
January 1976, Scandinavian journal of rheumatology. Supplement,
U Saarialho-Kere, and H Julkunen, and M J Mattila, and T Seppälä
January 1981, European journal of rheumatology and inflammation,
U Saarialho-Kere, and H Julkunen, and M J Mattila, and T Seppälä
May 1973, Rheumatology and rehabilitation,
U Saarialho-Kere, and H Julkunen, and M J Mattila, and T Seppälä
January 1981, European journal of rheumatology and inflammation,
U Saarialho-Kere, and H Julkunen, and M J Mattila, and T Seppälä
June 1976, International journal of clinical pharmacology and biopharmacy,
Copied contents to your clipboard!